Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

2.525 -0.295 (-10.46%)
Streaming Delayed Price Updated: 12:08 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Black Diamond Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
Via AB Newswire
News headline image
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug ↗
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows... 
Via Benzinga
News headline image
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Looking Into Black Diamond Therapeutic's Recent Short Interest ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutic: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024 ↗
BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024 ↗
BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutics Announces Changes to Board of Directors
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutations 
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying ↗
The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.